Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality

Keehn, Aryeh; Ludmir, Ethan B.; Taylor, Jacob; Rabbani, Farhang

doi:10.1007/s00345-016-1934-z

Cited by 26 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They observed no excess risks for 0.5-1 years, and they did report excess risks for the periods 1-5 years, 5-10 years, and 10+ years. Several studies showed in particular an increased risk for radiation-induced SPC for the period after 10 years of follow-up (9,10). However, in a PCa population with most cases aged between 60-80 years, especially excess SPC risks in the first 10 years are important since they will have eventually have the most impact on survival rates.…”

Section: Discussionmentioning

confidence: 99%

“…Many previous cohort studies in the 3DCRT era have addressed SPC risks in PCa survivor cohorts. They consistently reported limited excess SPC risks for mainly bladder and rectal cancer (6,7,9,10). The impact of IMRT dose distributions on SPC risks is a topical research question, addressed in many recent model studies, evaluating risks for different age categories and different IMRT features.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Risk of Second Primary Cancers in Prostate Cancer Survivors Treated in the Modern Radiotherapy Era

et al. 2020

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Risk of Second Primary Cancers in Prostate Cancer Survivors Treated in the Modern Radiotherapy Era

et al. 2020

View full text Add to dashboard Cite

“…Some important limitations of the present study are acknowledged. First and foremost, the study has the limitations of similar retrospective SEER database studies . Moreover, it is plausible that additional biases that originate from variables that are not included in the SEER database remained unaccounted for.…”

Section: Discussionmentioning

confidence: 99%

Long‐term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large‐scale population‐based analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…According to the Newcastle-Ottawa Quality Assessment Form for Cohort Studies, 12 studies had good qualities [14][15][16][17][18][19][20][21][22][23][24][25] and 14 studies have categorized in fair quality [26][27][28][29][30][31][32][33][34][35][36][37][38][39]. (Supplement Fig.…”

Section: Quality Assessmentmentioning

confidence: 99%

Risk of Secondary Malignancies in Patients with prostate cancer: A Systematic Review and Meta-analysis

Heydari

Rismantab

Shamshirian

et al. 2020

Preprint

View full text Add to dashboard Cite

IMPORTANCE: Prostate cancer (PC) is the second most common cancer among males globally, however, the survival rate is favorable in most patients. In a small number of patients, who suffer from advanced or invasive cancer, various side effects such as secondary malignancies or treatment-related secondary malignancies (SMs) may be seen. OBJECTIVE: To systematically asses the risk of secondary malignancies in patients with prostate cancer. DATA SOURCES: We have searched for longitudinal studies through databases of Web of Science, Scopus and PubMed for all available data up to September 2019. STUDY SELECTION: Studies with longitudinal design on prostate cancer patients that declared the results in SIR or those that the SIR could be calculated were eligible. DATA EXTRACTION AND SYNTHESIS: The heterogeneity was evaluated using the I2 test. According to the results and in case of I2 ≥ 50%, the random effect model was used to combine the results. To identify the cause of heterogeneity in the studies, the analysis of sub-groups was performed based on the site of secondary malignancy, the treatment procedure, and duration of follow-up. Data were analyzed using STATA version 11. MAIN OUTCOMES AND MEASURES: Overall SIR and based on treatment of prostate cancer and duration of follow-up. RESULTS: Twenty-six studies involving more than 2223,704 patients with PC and more than 86034 cases of SMs were entered into this study. The meta-analysis showed that the risk of cancer after PC was 1.03 (95% CI 0.90 - 1.15) and the SIRs of some cancers such as the bladder 1.52 (1.06 - 1.99) and melanoma 1.32 (0.78 - 1.87) were higher than expected. While, malignancies such as rectum 0.92 (0.85 - 1.00), lung 0.85 (0.74 - 0.96) and liver 0.76 (0.54 - 0.98) showed lower incidence in compare to general population. CONCLUSIONS AND RELEVANCE: The overall risk of SMs in patients with prostate cancer is not significantly different from general population, and even in patients undergoing prostatectomy or brachytherapy, the risk is lower. But the incidence of some cancers such as melanoma, bladder, and urinary tract appears to be higher than the public in all types of treatment approaches.

show abstract

Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality

Cited by 26 publications

References 26 publications

The Risk of Second Primary Cancers in Prostate Cancer Survivors Treated in the Modern Radiotherapy Era

The Risk of Second Primary Cancers in Prostate Cancer Survivors Treated in the Modern Radiotherapy Era

Long‐term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large‐scale population‐based analysis

Risk of Secondary Malignancies in Patients with prostate cancer: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About